Camillo Imbimbo

Camillo Imbimbo

Auto-generated profile, based on publicly available information

Camillo Imbimbo

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2025 in Ageing Research Reviews
Verified
Journal Article
Closed access
SLSimone Lista
Simone Lista
AMANTONIO MUNAFO'
ANTONIO MUNAFO'
FCFilippo Caraci
Filippo Caraci
CICamillo Imbimbo
Camillo Imbimbo
EEEnzo Emanuele
Enzo Emanuele
ASAlejandro Santos-Lozano
Alejandro Santos-Lozano

16 January 2024 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
SLSimone Lista
Simone Lista
ASAlejandro Santos-Lozano
Alejandro Santos-Lozano
EEEnzo Emanuele
Enzo Emanuele
Nicola Biagio MercuriNicola Biagio Mercuri
Nicola Biagio Mercuri
AGAudrey Gabelle
Audrey Gabelle
RNRobert Nistico
Robert Nistico

4 April 2024 in Ageing Research Reviews
Verified
Journal Article
Closed access
SLSimone Lista
Simone Lista
MMMark Mapstone
Mark Mapstone
FCFilippo Caraci
Filippo Caraci
EEEnzo Emanuele
Enzo Emanuele
SLSusana López-Ortiz
Susana López-Ortiz
Bruno Pietro ImbimboBruno Pietro Imbimbo
Bruno Pietro Imbimbo

2 December 2024 in CNS Drugs
Verified
Journal Article
Open access
PDF file
CICamillo Imbimbo
Camillo Imbimbo
MRMatteo Cotta Ramusino
Matteo Cotta Ramusino
SLSilvia Leone
Silvia Leone
FMFederico Mazzacane
Federico Mazzacane
VFValentino De Franco
Valentino De Franco
ACAlfredo Arturo Costa
Alfredo Arturo Costa
Psychosis and agitation are among the most distressing neuropsychiatric symptoms (NPSs) of Alzheimer’s disease (AD), linked to faster disease progression and earlier admission to nursing homes. While nonpharmacological treatments may alleviate mild behavioral symptoms, more severe syndromes often require pharmacological intervention. Brexpiprazole is the only medication approved for agitation in AD, although its limited clinical efficacy has raised criticism. No drugs have been approved for treating psychosis in AD, highlighting the critical need for new, effective, and safe treatments. Recent studies have elucidated part of the neurobiological basis of NPSs in the AD brain, offering insights for testing repurposed and novel drugs. We conducted a comprehensive nonsystematic literature review, aiming to provide a critical overview of both current treatments and emerging pharmacological interventions under clinical development for treating psychosis and agitation in AD. Additionally, we present strategies to optimize the clinical development of new drug candidates. We identify three promising compounds that are currently in phase 3 trials: xanomeline-trospium for AD psychosis, and dextromethorphan-bupropion and dexmedetomidine for agitation in AD. We propose that biomarkers linked to the neuropsychiatric traits of AD patients should be identified in dedicated studies and then included in phase 2 dose-range-finding studies with novel compounds to establish biological engagement. Furthermore, phase 3 placebo-controlled studies should be carried out in AD biomarker-confirmed subjects with narrower cognitive impairment ranges and precise NPS severity at screening. Alternative study designs, such as sequential phase approaches, may also be adopted.

12 March 2022 in Cerebral Circulation - Cognition and Behavior
Verified
Journal Article
Open access
CICamillo Imbimbo
Camillo Imbimbo
MSMarco Spallazzi
Marco Spallazzi
FFFrancesca Ferrari-Pellegrini
Francesca Ferrari-Pellegrini
AVAmanda Villa
Amanda Villa
AZAlessandro Zilioli
Alessandro Zilioli
DLDavide Lazzeroni
Davide Lazzeroni
Heart rate variability (HRV), a measure of autonomic function, has been associated with both cardiovascular disease and cognitive dysfunction. In turn, cardiovascular risk has been linked to an increased risk of dementia onset. However, whether autonomic dysfunction may represent an early marker of cognitive decline in individuals with high cardiovascular risk is still an open issue. We performed a complete 24-hour HRV analysis in 50 middle-aged and elderly subjects with cardiovascular risk as assessed with the European Society of Cardiology Systematic Coronary Risk Evaluation (ESC SCORE). Cognitive performance was evaluated by Montreal Cognitive Assessment (MoCA), Free and Cued Selective Reminding Test (FCSRT) and Stroop Color and Word Test. Stepwise regression was used to identify significant associations between 24-hour ambulatory ECGs parameters and cognitive performances. There were 30 women and 20 men with mean age of 64.9 years (range 51-77) and the mean ESC SCORE was 6%. Four subjects were diagnosed with mild cognitive impairment. Associations were found between measures of HRV and measures of cognition. Ultra-low frequency (ULF) band power of HRV significantly correlated with MoCA (r = 0.424, p = 0.003), also after adjustment for demographics and education. A significant association was also found between the ESC SCORE and ULF band power (r = -0.470, p = 0.0009). Ultra-low frequency band power of HRV is associated with cognitive performance of middle-aged and elderly subjects with cardiovascular risk. This finding may indicate that autonomic nervous system dysregulation plays a role in developing cardiovascular risk and cognitive decline.

1 July 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
GPGiulia Perini
Giulia Perini
MRMatteo Cotta Ramusino
Matteo Cotta Ramusino
MVMarco Vergani
Marco Vergani
AGAlberto Gatti
Alberto Gatti
CICamillo Imbimbo
Camillo Imbimbo
ACAlfredo Costa
Alfredo Costa
Background: Behavioral and psychological symptoms of dementia (BPSD) have poorly understood pathological/morphological correlates. Objective: We aimed to (1) investigate the perception of the utility of different biomarkers in the assessment of BPSD among Italian Memory Clinics and (2) review current literature in this regard. Methods: A multicenter, national survey was launched by the BPSD Study Group of the Italian Neurological Society for Dementia (SINdem). Participants completed a semi-structured questionnaire on their perception of possible associations between the occurrence/severity of different BPSD and different biomarkers, based on their individual knowledge and clinical experience, regarding any type and severity of cognitive impairment. Then, we performed a systematic review according to PRISMA guidelines. Only papers reporting biomarkers correlates of BPSD in neurocognitive disorders were included. Results: Among the 53 responders, 94%, 68%, 68%, and 45% perceived neuropsychological testing, MRI, FDG-PET, and EEG, respectively, associated with the total amount of BPSD. EEG alterations were perceived selectively associated with nighttime behavior disturbances and psychosis cluster (p < 0.01). Hallucinations, apathy and delusions were perceived as more correlated with biomarkers. Years of experience using biomarkers for diagnosis were associated with a more selective use of topographical biomarkers (p < 0.01). 91% of participants consider useful increasing the use of biomarkers to predict the occurrence/severity of BPSD. The literature review identified 99 eligible studies. Brain MRI (60 articles) and FDG-PET (12 studies) alterations are the most associated with BPSD. Conclusions: In clinical practice, topographical biomarkers related to regional consequences of the pathology are perceived as potentially informative in the BPSD's assessment.